Table 6.

Patient Disposition

ReasonPlacebo n (%)Atomoxetine (mg/kg/day)
0.5
n (%)
[95% CI]*
1.2
n (%)
[95% CI]*
1.8
n (%)
[95% CI]*
Completed72 (85.7)34 (77.3)69 (82.1)73 (85.9)
[−22.9, 6.0][−14.7, 7.5][−10.4, 10.7]
Adverse event0 (0.0)1 (2.3)2 (2.4)4 (4.7)
Personal conflict4 (4.8)3 (6.8)6 (7.1)4 (4.7)
[−6.7, 10.8][−4.8, 9.5][−6.5, 6.3]
Lack of efficacy4 (4.8)3 (6.8)2 (2.4)1 (1.2)
Lost to follow-up4 (4.8)3 (6.8)1 (1.2)2 (2.4)
Protocol violation/entry criteria not met0 (0.0)0 (0.0)2 (2.4)1 (1.2)
Patient moved0 (0.0)0 (0.0)1 (1.2)0 (0.0)
Physician decision0 (0.0)0 (0.0)1 (1.2)0 (0.0)
  • P = .054 Cochran-Armitage test for a dose-response trend.

  • *  95% confidence intervals (CI) on pairwise differences (atomoxetine-placebo) are reported when the overall event incidence is at least 5%.